A Real-world Study of Brentuximab Vedotin Monotherapy and Combination Regimens in the Treatment of Relapsed/Refractory Hodgkin Lymphoma
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Bendamustine; Dacarbazine; Etoposide; Gemcitabine; Sintilimab; Tislelizumab
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 13 Jan 2025 New trial record